Literature DB >> 20671227

Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.

Bjarne Orskov1, Vibeke Rømming Sørensen, Bo Feldt-Rasmussen, Svend Strandgaard.   

Abstract

BACKGROUND AND OBJECTIVES: The introduction of new therapies, including agents that block the renin-angiotensin system, may have affected progression of autosomal dominant polycystic kidney disease (ADPKD). We investigated whether the age when reaching ESRD and survival during renal replacement therapy in Danish patients with ADPKD changed from January 1, 1990, through December 31, 2007. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: According to the Danish National Registry on Regular Dialysis and Transplantation, 693 patients with ADPKD reached ESRD in the study period. The 18 years were divided into three consecutive 6-year intervals.
RESULTS: The incidence of reaching ESRD for patients with ADPKD increased from 6.45 per million people in 1990 through 1995 to 7.59 per million people in 2002 through 2007, and the mean age at onset of ESRD increased by 4.7 years. The age-adjusted male-to-female ratio for onset of ESRD changed from 1.6 to 1.1, indicating a trend toward similar progression in both genders. From onset of ESRD, a Cox regression analysis to compare the first and second 6-year intervals, adjusted for age, gender, and treatment modality, showed that patient survival improved by 38%. Although NS, a similar trend was found during the second and third time intervals.
CONCLUSIONS: This study demonstrates that in Danish patients with ADPKD, the prognosis had significantly improved during the study period. Furthermore, the results indicate that male gender may be losing its importance as a risk factor for progression in ADPKD.

Entities:  

Mesh:

Year:  2010        PMID: 20671227      PMCID: PMC3001783          DOI: 10.2215/CJN.01460210

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  28 in total

1.  Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kimberly K McFann; Ann M Johnson
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

Review 2.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

3.  Progress in blood pressure control in autosomal dominant polycystic kidney disease.

Authors:  T Ecder; C L Edelstein; G M Fick-Brosnahan; A M Johnson; I T Duley; P A Gabow; R W Schrier
Journal:  Am J Kidney Dis       Date:  2000-08       Impact factor: 8.860

4.  Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.

Authors:  T Ecder; A B Chapman; G M Brosnahan; C L Edelstein; A M Johnson; R W Schrier
Journal:  Am J Kidney Dis       Date:  2000-03       Impact factor: 8.860

Review 5.  Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.

Authors:  Catherine R Lawson; Timothy W Doulton; Graham A MacGregor
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2006-09       Impact factor: 1.636

6.  Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999.

Authors:  Bénédicte Stengel; Solenne Billon; Paul C W Van Dijk; Kitty J Jager; Friedo W Dekker; Keith Simpson; J Douglas Briggs
Journal:  Nephrol Dial Transplant       Date:  2003-09       Impact factor: 5.992

7.  The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration.

Authors:  Kristine Hommel; Søren Rasmussen; Mette Madsen; Anne-Lise Kamper
Journal:  Nephrol Dial Transplant       Date:  2009-10-26       Impact factor: 5.992

8.  Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease.

Authors:  Sule Namli; Hüseyin Oflaz; Faruk Turgut; Sabahat Alisir; Fatih Tufan; Adem Ucar; Fehmi Mercanoglu; Tevfik Ecder
Journal:  Ren Fail       Date:  2007       Impact factor: 2.606

9.  Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.

Authors:  Robert Schrier; Kimberly McFann; Ann Johnson; Arlene Chapman; Charles Edelstein; Godela Brosnahan; Tevfik Ecder; Lyn Tison
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

10.  Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years.

Authors:  Elizabeth Dicks; Pietro Ravani; Deanna Langman; William S Davidson; York Pei; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2006-06-08       Impact factor: 8.237

View more
  23 in total

1.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

2.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

3.  Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Authors:  Vicente E Torres; Arlene B Chapman; Ronald D Perrone; K Ty Bae; Kaleab Z Abebe; James E Bost; Dana C Miskulin; Theodore I Steinman; William E Braun; Franz T Winklhofer; Marie C Hogan; Frederic R Oskoui; Cass Kelleher; Amirali Masoumi; James Glockner; Neil J Halin; Diego R Martin; Erick Remer; Nayana Patel; Ivan Pedrosa; Louis H Wetzel; Paul A Thompson; J Philip Miller; Catherine M Meyers; Robert W Schrier
Journal:  Kidney Int       Date:  2011-12-28       Impact factor: 10.612

4.  Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease.

Authors:  Lilia R Lukowsky; Miklos Z Molnar; Joshua J Zaritsky; John J Sim; Istvan Mucsi; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2011-12-29       Impact factor: 5.992

5.  Liver involvement in early autosomal-dominant polycystic kidney disease.

Authors:  Marie C Hogan; Kaleab Abebe; Vicente E Torres; Arlene B Chapman; Kyongtae T Bae; Cheng Tao; Hongliang Sun; Ronald D Perrone; Theodore I Steinman; William Braun; Franz T Winklhofer; Dana C Miskulin; Frederic Rahbari-Oskoui; Godela Brosnahan; Amirali Masoumi; Irina O Karpov; Susan Spillane; Michael Flessner; Charity G Moore; Robert W Schrier
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-09       Impact factor: 11.382

Review 6.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

7.  Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Marie E Edwards; Fouad T Chebib; Maria V Irazabal; Troy G Ofstie; Lisa A Bungum; Andrew J Metzger; Sarah R Senum; Marie C Hogan; Ziad M El-Zoghby; Timothy L Kline; Peter C Harris; Frank S Czerwiec; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-19       Impact factor: 8.237

8.  Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Berenice Reed; Pamela Mettler; Kim Mc Fann; Oleksandra Tkachenko; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Nephrol       Date:  2012-10-04       Impact factor: 3.754

Review 9.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06

Review 10.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.